Virtual Poster Session in Oncology/Hematology
Virtual Poster
Virtual Poster

Virtual Poster Session in Oncology/Hematology

Practical Application of Key Data Presented During the 2017 Oncology Annual Meeting in Chicago

Not a member of My prIME? Join now for instant access.

View CME-certified abstract presentations and downloadable slides covering the most up-to-date clinical trial data in gastrointestinal, gynecologic, and lung cancer, as well as hematology, from the 2017 Oncology Annual Meeting in Chicago.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

5.25 AMA PRA Category 1 Credits

Release Date

Release Date

Jun 9, 2017

Expiration Date

Jun 9, 2018

Gastrointestinal Cancer

Thierry André, MD

Abstract #3531: Combination of nivolumab (nivo) + ipilimumab (ipi) in the treatment of patients (pts) with deficient DNA mismatch repair (dMMR)/high microsatellite instability (MSI-H) metastatic colorectal cancer (mCRC): CheckMate 142 study

Click here to view abstract

Featured Expert: Thierry André, MD

Axel Grothey, MD

Abstract #3551: Hand-foot skin reaction (HFSR) and outcomes in the phase 3 CORRECT trial of regorafenib for metastatic colorectal cancer (mCRC).

Click here to view abstract

Featured Expert: Axel Grothey, MD

Axel Grothey, MD

Abstract #3558: Response to pembrolizumab in patients with mismatch repair deficient (dMMR) colorectal cancer (CRC)

Click here to view abstract

Featured Expert: Axel Grothey, MD

Michel Ducreux, MD, PhD

Abstract #3567: Impact of tumor location on outcomes in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): An interim analysis from the prospective, observational CORRELATE study

Click here to view abstract

Featured Expert: Michel Ducreux, MD, PhD

Qian Shi, PhD

Abstract #LBA1: Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration

Click here to view abstract

Featured Expert: Qian Shi, PhD

Richard Finn, MD

Abstract #4001: Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC)

Click here to view abstract

Featured Expert: Richard Finn, MD

Charles S. Fuchs, MD, MPH

Abstract #4003: KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer

Click here to view abstract

Featured Expert: Charles S. Fuchs, MD, MPH

Yung-Jue Bang, MD, PhD

Abstract #4012: KEYNOTE-059 cohort 2: Safety and efficacy of pembrolizumab (pembro) plus 5-fluorouracil (5-FU) and cisplatin for first-line (1L) treatment of advanced gastric cancer

Click here to view abstract

Featured Expert: Yung-Jue Bang, MD, PhD

Jordi Bruix, MD, PhD

Abstract #4078: Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis

Click here to view abstract

Featured Expert: Jordi Bruix, MD, PhD

Gynecologic Cancer

Michael Friedlander, MD, PhD

Abstract #5507: Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial

Click here to view abstract

Featured Expert: Michael Friedlander, MD, PhD

Mansoor R. Mirza, MD

Abstract #5517: Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy

Click here to view abstract

Featured Expert: Mansoor R. Mirza, MD

Bradley J. Monk, MD, FACS, FACOG

Abstract #5534: Long-term benefit of niraparib treatment of recurrent ovarian cancer (OC)

Click here to view abstract

Featured Expert: Bradley J. Monk, MD, FACS, FACOG

Kathleen Moore, MD

Abstract #5547: Mirvetuximab soravtansine (IMGN853), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in platinum-resistant epithelial ovarian cancer (EOC) patients (pts): Activity and safety analyses in phase I pooled expansion cohorts

Click here to view abstract

Featured Expert: Kathleen Moore, MD

David  O’Malley, MD

Abstract #5553: Safety findings from FORWARD II: A phase 1b study evaluating the folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) mirvetuximab soravtansine (IMGN853) in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin (PLD), or pembrolizumab in patients (pts) with ovarian cancer

Click here to view abstract

Featured Expert: David O’Malley, MD

Hematology

Richard M. Stone, MD

Abstract #7016: Effect of cytarabine/anthracycline/crenolanib induction on minimal residual disease (MRD) in newly diagnosed FLT3 mutant AML.

Click here to view abstract

Featured Expert: Richard M. Stone, MD

Naval G. Daver, MD

Abstract #7026: Phase IB/II study of nivolumab with azacytidine (AZA) in patients (pts) with relapsed AML.

Click here to view abstract

Featured Expert: Naval G. Daver, MD

Jeffrey Lancet, MD

Abstract #7035: Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.

Click here to view abstract

Featured Expert: Jeffrey Lancet, MD

Bruno C. Medeiros, MD

Abstract #7036: Efficacy by consolidation administration site: Subgroup analysis of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML).

Click here to view abstract

Featured Expert: Bruno C. Medeiros, MD

Stephan A. Grupp, MD, PhD

Abstract #7047: Timing of initiation of defibrotide (DF) post-diagnosis of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after hematopoietic stem cell transplantation (HSCT): Final data from an expanded-access protocol.

Click here to view abstract

Featured Expert: Stephan A. Grupp, MD, PhD

Jeff Sharman, MD

Abstract #7502: Phase IIIb randomized study of lenalidomide plus rituximab (R2) followed by maintenance in relapsed/refractory NHL: Analysis of patients with double-refractory or early relapsed follicular lymphoma (FL)

Click here to view abstract

Featured Expert: Jeff Sharman, MD

Loretta Nastoupil, MD

Abstract #7519: Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study

Click here to view abstract

Featured Expert: Loretta Nastoupil, MD

Gilles Salles, MD, PhD

Abstract #7536: Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Click here to view abstract

Featured Expert: Gilles Salles, MD, PhD

Stephan A. Grupp, MD, PhD

Abstract #10513: Efficacy and safety of defibrotide (DF) to treat hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) after primary chemotherapy (CT): A post hoc analysis of final data.

Click here to view abstract

Featured Expert: Stephan A. Grupp, MD, PhD

Lung Cancer

Jamie E. Chaft, MD

Abstract #8508: Neoadjuvant nivolumab in early-stage, resectable non-small cell lung cancers

Click here to view abstract

Featured Expert: Jamie E. Chaft, MD

Julie Brahmer, MD

Abstract #9000: Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) ≥50% enrolled in KEYNOTE-024

Click here to view abstract

Featured Expert: Julie Brahmer, MD

Fernando Costa Santini, MD

Abstract #9012: Safety of retreatment with immunotherapy after immune-related toxicity in patients with lung cancers treated with anti-PD(L)-1 therapy

Click here to view abstract

Featured Expert: Fernando Costa Santini, MD

Ahmad Tarhini, MD

Abstract #9014: Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I/II results of ECHO-202/KEYNOTE-037

Click here to view abstract

Featured Expert: Ahmad Tarhini, MD

Suresh Ramalingam, MD

Abstract #9094: First-Line Carboplatin and Pemetrexed (CP) With or Without Pembrolizumab (Pembro) for Advanced Nonsquamous NSCLC: Updated Results of KEYNOTE-021 Cohort G

Click here to view abstract

Featured Expert: Suresh Ramalingam, MD

  • Thierry André, MDHopital Saint Antoine
    Paris, France
  • Yung-Jue Bang, MD, PhDSeoul National University Hospital
    Seoul, Korea
  • Julie Brahmer, MDSidney Kimmel Comprehensive Cancer Center
    Johns Hopkins University
    Baltimore, Maryland, United States
  • Jordi Bruix, MD, PhDUniversity of Barcelona
    Barcelona, Spain
  • Jamie E. Chaft, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Naval G. Daver, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Michel Ducreux, MD, PhDGustave Roussy
    Villejuif, France
  • Richard Finn, MDUCLA Medical Center
    Santa Monica, California, United States
  • Michael Friedlander, MD, PhDUniversity of New South Wales
    Prince of Wales Cancer Centre
    Sydney, Australia
  • Charles S. Fuchs, MD, MPHYale Cancer Center
    New Haven, Connecticut, United States
  • Axel Grothey, MDMayo Clinic
    Rochester, Minnesota, United States
  • Stephan A. Grupp, MD, PhDChildren’s Hospital of Philadelphia
    Philadelphia, Pennsylvania, United States
  • Jeffrey Lancet, MDMoffit Cancer Center
    Tampa, Florida, United States
  • Bruno C. Medeiros, MDStanford University Medical Center
    Palo Alto, California, United States
  • Mansoor R. Mirza, MDCopenhagen University Hospital
    Rigshospitalet
    Copenhagen, Denmark
  • Bradley J. Monk, MD, FACS, FACOGArizona Oncology (US Oncology Network), University of Arizona College of Medicine-Phoenix
    Creighton University School of Medicine at St. Joseph's Hospital
    Phoenix, Arizona, United States
  • Kathleen Moore, MDStephenson Cancer Center
    University of Oklahoma
    Oklahoma City, Oklahoma, United States
  • Loretta Nastoupil, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • David O’Malley, MDThe Ohio State University
    James Comprehensive Cancer Center
    Columbus, Ohio, United States
  • Suresh Ramalingam, MDWinship Cancer Institute
    Emory University
    Atlanta, Georgia, United States
  • Gilles Salles, MD, PhDUniversity of Lyon
    Lyon, France
  • Fernando Costa Santini, MDMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Jeff Sharman, MDWillamette Valley Cancer Institute/US Oncology Research
    Springfield, Oregon, United States
  • Qian Shi, PhDMayo Clinic
    Rochester, Minnesota, United States
  • Richard M. Stone, MDDana-Farber Cancer Institute
    Boston, Massachusetts, United States
  • Ahmad Tarhini, MD University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania

This activity is specifically designed to meet the needs of medical, surgical, and radiation oncologists, hematologists, and other healthcare professionals involved in the treatment of patients with cancer.

After successful completion of this educational activity, participants should be able to:

  • Evaluate emerging clinical trial data for new and emerging agents and compare with established therapy options

This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; ImmunoGen, Inc.; Jazz Pharmaceuticals; Merck and Co, Inc.; and TESARO, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Virtual Poster Session in Oncology/Hematology - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each module may provide the following credits:

  • Gastrointestinal Cancer: 1.75
  • Gynecologic Cancer: 1.0
  • Hematology: 1.75
  • Lung Cancer: 1.0

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

A link to the posttest is available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Faculty Disclosures
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr André has disclosed that he has received consulting fees from Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Bang has disclosed that he has received consulting fees from MSD. He has also performed contracted research for MSD through his institution. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Brahmer has disclosed that she has received consulting fees from Bristol-Myers Squibb (uncompensated), Celgene, Lilly, and Merck. She has performed contracted research for Bristol-Myers Squibb, MedImmune/Astrazeneca, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Bruix has disclosed that he has received consulting fees from Abbott, AbbVie, Arqule, Bayer, Biocompatibles, Boehringer Ingelheim, Bristol-Myers Squibb, Daichi, Gilead, GlaxoSmithKline, Kowa, Lilly, Novartis, Onxeo, Roche, and Terumo. He has also performed contracted research for Bayer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Chaft has disclosed that she has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, and Merck. She has agreed to disclose any unlabeled/unapproved uses of drugs referenced in her presentation.

Dr Daver has disclosed that he has received consulting fees from Incyte, Novartis Oncology, and Otsuka. He has also performed contracted research for Bristol-Myers Squibb, Daiichi Sankyo, Kiveric Pharma, Incyte, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ducreux has has disclosed that he has received consulting fees from Roche, Merck Serono, Novartis, Servier, Lilly, and Celgene. He has also performed contracted research for Pfizer, Roche, and Merck Serono. Furthermore, his wife is head of the Business Oncology Unit at Sandoz. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Finn has disclosed that he has received consulting fees from Bayer, Bristol-Myers Squibb, Novartis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Friedlander has disclosed that he has participated in advisory boards or in a consultancy role for AstraZeneca and received honoraria from AstraZeneca and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Fuchs has disclosed that he has received consulting fees from Agios, Bayer, Dicerna, Eli Lilly, Entrinsic Health, Five Prime Therapeutics, Genentech, Gilead Sciences, Kew, Merck, Merrimack, Sanofi, and Taiho. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Grothey has disclosed that he has received consulting fees from Bayer, Boehringer Ingelheim, Boston Biomedicals, Eli-Lilly, Genentech, and Taiho. He also disclosed performing contracted research for Bayer, Boston Biomedicals, and Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Grupp has disclosed that he has received consulting fees from Jazz Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lancet has disclosed that he has received consulting fees from Jazz. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Medeiros has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Mirza has disclosed that he has received consulting fees from Advaxis, AstraZeneca, Boehringer Ingelheim, Cerulean, Clovis Oncology, Genmab, Karyopharm Therapeutics, Novocure, Pfizer, Roche, and Tesaro. He has also received study grants from AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Pfizer, Roche, and Tesaro. He serves on the board of directors for Karyopharm Therapeutics Inc., Metamark Genetics, and Sera Prognostics Inc. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

Dr Monk has disclosed that he has performed contracted research for Amgen, Array, Genentech, Janssen/Johnson & Johnson, Lilly, Morphotek, and Tesaro. He has also received consultation fees from Advaxis, Amgen, AstraZeneca, Bayer, Clovis, Gradalis, Insys, Mateon, Merck, Pfizer, PPD, Roche/Genentech, and Tesaro. He has also received fees for non-CME services received directly from commercial interest from AstraZeneca, Janssen/Johnson & Johnson, Myriad, and Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Moore has disclosed that she has received consulting fees from AdvaCare, AstraZeneca, Clovis Oncology, Genentech/Roche, Immunogen, Tesaro, and VBL Therapeutics. She has agreed to disclose any unlabeled/unapproved uses of drugs referenced in her presentation.

Dr Nastoupil has disclosed that she has performed contracted research for AbbVie, Celgene, Genentech, Janssen, and TG Therapeutics. She has agreed to disclose any unlabeled/unapproved uses of drugs referenced in her presentation.

Dr O’Malley has disclosed his institution has received Immunogen research support. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ramalingam has disclosed that he has received consulting fees from Abbvie, Amgen, AstraZeneca, Boehringer Ingelheim, BMS, Celgene, Genentech, Lilly, Merck, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Salles has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb/Roche, Celgene/Gilead, Janssen, and Merck. He has also performed contracted research for Roche. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Santini has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Shi has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sharman has disclosed that he has received consulting fees from and performed contracted research for AbbVie, Acerta, Celgene, Genentech, Gilead, and TG Therapeutics. He has also received fees for non-CME services from Gilead. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.

Dr Stone has disclosed that he has received consulting fees from Arog Pharmaceuticals, Astellas, Agios, AbbVie, Amgen, Celgene, FUJIFILM Pharmaceuticals, Novartis Oncology, Orsenix, Ono Pharmaceutical, Jazz, Pfizer, and Sumitomo. He also disclosed performing contracted research for or receiving research support from Novartis. He has received other funding for participating in the data and safety monitoring board for Argenix/Celgene. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Tarhini has disclosed that he has performed contracted research for Incyte and Merck. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Elizabeth Cameron, PhD (clinical content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.